Gilead Sciences Inc. will undercut the prices of its own blockbuster hepatitis C drugs beginning in 2019 by offering authorized generics of Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) at more than 60% discounts to the brands.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?